1. bookVolume 22 (2014): Issue 3 (September 2014)
Journal Details
First Published
08 Aug 2013
Publication timeframe
4 times per year
access type Open Access

A glance on recent progresses in diagnosis and treatment of primary immunodeficiencies/ Progrese recente în diagnosticul şi tratamentul imunodeficienţelor primare

Published Online: 08 Oct 2014
Page range: 297 - 309
Received: 06 Jul 2014
Accepted: 25 Aug 2014
Journal Details
First Published
08 Aug 2013
Publication timeframe
4 times per year

Primary immunodeficiencies (PIDs)* belong to the group of rare diseases which need more awareness by the relevant medical disciplines. Below a review on recent progresses in diagnosis and treatment of PIDs is given. Reducing the regrettable delay in diagnosis of PIDs (worldwide) is possible only when awareness is increased by doctors who may encounter patients with PID. This review shall serve this purpose. Progresses in understanding what the link might be between one genetic defect presenting in various phenotypes or how various gene defects may manifest by very similar PID phenotypes helps building awareness. Knowledge of PID favours early diagnosis, a cornerstone of optimal, sometimes life-long care at justifiable costs. The complexity of PIDs calls for clinical laboratory and clinical diagnostic performed by experts only. Exciting laboratory diagnostic progresses in early diagnosis of the most severe forms of PID are reviewed below. Progresses in curative therapies for PIDs, such as hematopoietic stem cell transplantation and gene therapies, are mentioned in short. About 80% of PID patients suffer from an antibody deficiency syndrome and can profit from non-curative replacement therapies with human immunoglobulin G concentrates. Modes of application, safety and hints for dosing of replacement therapies to reduce frequencies of severe infections are mentioned below. Thanks to the increasing quality of care, patients survive adolescence. A glance is given on the problems of transition to the adult medicine setting.


1. Casanova JL, Abel L. The genetic theory of infectious diseases: A brief history and selected illustrations. Annu Rev Genomics Hum Genet. 2013;14:215-43. DOI: 10.1146/annurev-genom-091212-15344810.1146/annurev-genom-091212-153448498076123724903Search in Google Scholar

2. Pandolfi F, Milito C, Conti V, Pagliari D, Frosali S, Cianci R, et al. Common variable immunodeficiency - New insight into the pathogenesis and the quest for a workable classification. J Biol Regul Homeost Agents. 2013;27(2):285-9.Search in Google Scholar

3. Maggina P, Gennery AR. Classification of primary immunodeficiencies: need for a revised approach? J Allergy Clin Immunol. 2013 Feb;131(2):292-4. DOI: 10.1016/j.jaci.2012.10.00810.1016/j.jaci.2012.10.00823174660Search in Google Scholar

4. Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: An update on the classification from the International Union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;5(APR). DOI: 10.3389/ fimmu.2014.0016210.3389/fimmu.2014.00460Search in Google Scholar

5. Chinen J, Notarangelo LD, Shearer WT. Advances in basic and clinical immunology in 2013. J Allergy Clin Immunol. 2014 Feb 28;133(4):967-76. DOI: 10.1016/j. jaci.2014.01.026Search in Google Scholar

6. Hernandez-Trujillo V. New genetic discoveries and primary immune deficiencies. Clin Rev Allergy Immunol. 2014;46(2):145-53. DOI: 10.1007/s12016-013-8380-010.1007/s12016-013-8380-023860595Search in Google Scholar

7. Gathmann B, Binder N, Ehl S, Kindle G. The European internet-based patient and research database for primary immunodeficiencies: Update 2011. Clin Exp Immunol. 2012;167(3):479-91. DOI: 10.1111/j.1365-2249.2011.04542.x10.1111/j.1365-2249.2011.04542.x337428022288591Search in Google Scholar

8. Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013 Jan;33(1):1-7. DOI: 10.1007/s10875-012-9751-710.1007/s10875-012-9751-722847546Search in Google Scholar

9. Chapel H, Lucas M, Lee M, Björkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008 Jul 15;112(2):277-86. DOI: 10.1182/blood-2007-11-12454510.1182/blood-2007-11-12454518319398Search in Google Scholar

10. Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008 Jan 1;111(1):77-85. DOI: 10.1182/blood-2007-06-09174410.1182/blood-2007-06-09174417898316Search in Google Scholar

11. Baldovino S, Montin D, Martino S, Sciascia S, Menegatti E, Roccatello D. Common variable immunodeficiency: crossroads between infections, inflammation and autoimmunity. Autoimmun Rev. 2013 Jun;12(8):796-801. DOI: 10.1016/j.autrev.2012.11.00310.1016/j.autrev.2012.11.00323219764Search in Google Scholar

12. Gathmann B, Mahlaoui N, Gerard L, Oksenhendler E, Warnatz K, Schulze I, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014 Feb 27;Epub ahead of print. DOI: 10.1016/j.jaci.2013.12.107710.1016/j.jaci.2013.12.107724582312Search in Google Scholar

13. Eibel H, Salzer U, Warnatz K. Common variable immunodeficiency at the end of a prospering decade: Towards novel gene defects and beyond. Curr Opin Allergy Clin Immunol. 2010;10(6):526-33. DOI: 10.1097/ ACI.0b013e32833fea1c10.1097/ACI.0b013e32833fea1cSearch in Google Scholar

14. Keller MD, Jyonouchi S. Chipping away at a mountain: Genomic studies in common variable immunodeficiency. Autoimmun Rev. 2013;12(6):687-9. DOI: 10.1016/j.autrev.2012.10.01710.1016/j.autrev.2012.10.017Search in Google Scholar

15. Todoric K, Koontz JB, Mattox D, Tarrant TK. Autoimmunity in immunodeficiency. Curr Allergy Asthma Rep. 2013;13(4):361-70. DOI: 10.1007/s11882-013-0350-310.1007/s11882-013-0350-3Search in Google Scholar

16. Bousfiha AA, Jeddane L, Ailal F, Al HW, Conley ME, Cunningham-Rundles C, et al. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol. 2013 Aug;33(6):1078-87. DOI: 10.1007/s10875-013-9901-610.1007/s10875-013-9901-6Search in Google Scholar

17. Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, et al. Global study of primary immunodeficiency diseases (PI)-diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011 Oct;51(1):61-70. DOI: 10.1007/s12026-011-8241-y10.1007/s12026-011-8241-ySearch in Google Scholar

18. Routes J, Abinun M, Al-Herz W, Bustamante J, Condino- Neto A, de la Morena MT, et al. ICON: The early diagnosis of congenital immunodeficiencies. J Clin Immunol. 2014 May;34(4):398-424. DOI: 10.1007/ s10875-014-0003-xSearch in Google Scholar

19. Modell F, Puente D, Modell V. From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of Primary Immunodeficiencies. Immunol Res. 2009;44(1-3):132-49. DOI: 10.1007/s12026-008-8092-310.1007/s12026-008-8092-3Search in Google Scholar

20. Borte S, Borte M. Decreasing time-to-diagnosis in primary antibody deficiencies - The case for newborn screening programmes and awareness campaigns. Eur Infect Dis. 2012;6(2):99-104.Search in Google Scholar

21. MacGinnitie A, Aloi F, Mishra S. Clinical characteristics of pediatric patients evaluated for primary immunodeficiency. Pediatr Allergy Immunol. 2011;22(7):671-5. DOI: 10.1111/j.1399-3038.2011.01167.x10.1111/j.1399-3038.2011.01167.xSearch in Google Scholar

22. Motamed F, Aghamohammadi A, Soltani M, Mansouri M, Rezaei N, Teimourian S, et al. Evaluation of liver diseases in Iranian patients with primary antibody deficiencies. Ann Hepatol. 2009 Jul;8(3):196-202.10.1016/S1665-2681(19)31765-XSearch in Google Scholar

23. Dehkordy SF, Aghamohammadi A, Ochs HD, Rezaei N. Primary immunodeficiency diseases associated with neurologic manifestations. J Clin Immunol. 2012;32(1):1-24. DOI: 10.1007/s10875-011-9593-810.1007/s10875-011-9593-822038677Search in Google Scholar

24. Agarwal S, Mayer L. Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. Clin Gastroenterol Hepatol. 2013;11(9):1050-63. DOI: 10.1016/j.cgh.2013.02.02410.1016/j.cgh.2013.02.024380020423501398Search in Google Scholar

25. Hosseinverdi S, Hashemi H, Aghamohammadi A, Ochs HD, Rezaei N. Ocular involvement in primary immunodeficiency diseases. J Clin Immunol. 2014;34(1):23-38. DOI: 10.1007/s10875-013-9974-210.1007/s10875-013-9974-224292697Search in Google Scholar

26. Lehman H. Skin manifestations of primary immune deficiency. Clin Rev Allergy Immunol. 2014;46(2):112-9. DOI: 10.1007/s12016-013-8377-810.1007/s12016-013-8377-823760761Search in Google Scholar

27. Wood P. Primary antibody deficiencies: Recognition, clinical diagnosis and referral of patients. Clin Med (Lond Engl). 2009;9(6):595-9. DOI: 10.7861/clinmedicine. 9-6-595Search in Google Scholar

28. Abraham RS. Relevance of laboratory testing for the diagnosis of primary immunodeficiencies: A review of case-based examples of selected immunodeficiencies. Clin Mol Allergy. 2011;9:6. DOI: 10.1186/1476-7961-9-610.1186/1476-7961-9-6308080721477322Search in Google Scholar

29. de Vries E, European Society for Immunodeficiencies (ESID) members. Patient-centred screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. Clin Exp Immunol. 2012 Jan;167(1):108-19. DOI: 10.1111/j.1365-2249.2011.04461.x10.1111/j.1365-2249.2011.04461.x324809222132890Search in Google Scholar

30. Locke BA, Dasu T, Verbsky JW. Laboratory diagnosis of primary immunodeficiencies. Clin Rev Allergy Immunol. 2014 Apr;46(2):154-68. DOI: 10.1007/s12016-014-8412-410.1007/s12016-014-8412-424569953Search in Google Scholar

31. Borte S, Von Dobeln U, Hammarström L. Guidelines for newborn screening of primary immunodeficiency diseases. Curr Opin Hematol. 2013;20(1):48-54. DOI: 10.1097/MOH.0b013e32835a913010.1097/MOH.0b013e32835a913023108220Search in Google Scholar

32. Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014;133(4):1092-8. DOI: 10.1016/j.jaci.2013.09.04410.1016/j.jaci.2013.09.044397226624290292Search in Google Scholar

33. Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2005 Feb;115(2):391-8. DOI: 10.1016/j.jaci.2004.10.01210.1016/j.jaci.2004.10.01215696101Search in Google Scholar

34. Janik DK, Lindau-Shepard B, Comeau AM, Pass KA. A multiplex immunoassay using the Guthrie specimen to detect T-cell deficiencies including severe combined immunodeficiency disease. Clin Chem. 2010 Sep;56(9):1460-5. DOI: 10.1373/ clinchem.2010.14432910.1373/clinchem.2010.144329322018320660143Search in Google Scholar

35. Borte S, Von Döbeln U, Fasth A, Wang N, Janzi M, Winiarski J, et al. Neonatal screening for severe prima ry immunodeficiency diseases using high-throughput triplex real-time PCR. Blood. 2012;119(11):2552-5. DOI: 10.1182/blood-2011-08-37102110.1182/blood-2011-08-37102122130802Search in Google Scholar

36. Chiarini M, Zanotti C, Serana F, Sottini A, Bertoli D, Caimi L, et al. T-cell receptor and K-deleting recombination excision circles in newborn screening of Tand B-cell defects: Review of the literature and future challenges. J Public Health Res. 2013;2(1):9-16. DOI: 10.4081/jphr.2013.e310.4081/jphr.2013.e3414032225170474Search in Google Scholar

37. Serana F, Chiarini M, Zanotti C, Sottini A, Bertoli D, Bosio A, et al. Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies. J Transl Med. 2013;11:119. DOI: 10.1186/1479-5876-11-11910.1186/1479-5876-11-119366688923656963Search in Google Scholar

38. la Marca G. Mass spectrometry in clinical chemistry: the case of newborn screening. J Pharm Biomed Anal. 2014 Apr 28;E pub ahead of print. DOI: 10.1016/j. jpba.2014.03.047Search in Google Scholar

39. Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013;174(2):203-11. DOI: 10.1111/cei.1217810.1111/cei.12178382882323859429Search in Google Scholar

40. Seppänen M, Aghamohammadi A, Rezaei N. Is there a need to redefine the diagnostic criteria for common variable immunodeficiency? Expert Rev Clin Immunol. 2014;10(1):1-5. DOI: 10.1586/1744666X.2014.87047810.1586/1744666X.2014.87047824325452Search in Google Scholar

41. Nijman IJ, Van Montfrans JM, Hoogstraat M, Boes ML, Van De Corp, Renner ED, et al. Targeted next-generation sequencing: A novel diagnostic tool for primary immunodeficiencies. J Allergy Clin Immunol. 2014;133(2):529-34. DOI: 10.1016/j.jaci.2013.08.03210.1016/j.jaci.2013.08.03224139496Search in Google Scholar

42. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663-76. DOI: 10.1016/j.cell.2006.07.02410.1016/j.cell.2006.07.02416904174Search in Google Scholar

43. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007 Nov 30;131(5):861-72. DOI: 10.1016/j. cell.2007.11.019Search in Google Scholar

44. Pessach IM, Ordovas-Montanes J, Zhang SY, Casanova JL, Giliani S, Gennery AR, et al. Induced pluripotent stem cells: A novel frontier in the study of human primary immunodeficiencies. J Allergy Clin Immunol. 2011;127(6):1400-7. DOI: 10.1016/j.jaci.2010.11.00810.1016/j.jaci.2010.11.008308199321185069Search in Google Scholar

45. Hernandez-Trujillo HS, Chapel H, Lo RI, V, Notarangelo LD, Gathmann B, Grimbacher B, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol. 2012 Jul;169(1):57-69. DOI: 10.1111/j.1365-2249.2012.04588.x10.1111/j.1365-2249.2012.04588.x339047422670779Search in Google Scholar

46. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006 Apr;117(4 Suppl): S525-S553. DOI: 10.1016/j.jaci.2006.01.01510.1016/j.jaci.2006.01.01516580469Search in Google Scholar

47. Stonebraker JS, Farrugia A, Gathmann B, ESID Registry Woking Party, Orange JS. Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin. J Clin Immunol. 2014 Feb;34(2):233-44. DOI: 10.1007/s10875-013-9975-110.1007/s10875-013-9975-124338563Search in Google Scholar

48. Robinson P, Anderson D, Brouwers M, Feasby TE, Hume H. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev. 2007 Apr;21(2 Suppl 1):S3-S8. DOI: 10.1016/j.tmrv.2007.01.00410.1016/j.tmrv.2007.01.00417397767Search in Google Scholar

49. Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev. 2010 Jan;24(Suppl. 1):S28-S50. DOI: 10.1016/j. tmrv.2009.09.011Search in Google Scholar

50. Sewell WC, Kerr J, Behr-Gross ME, Peter HH. European consensus proposal for immunoglobulin therapies. Eur J Immunol. 2014 Jun 28. DOI: 10.1002/ eji.201444700Search in Google Scholar

51. Beauté J, Levy P, Millet V, Debré M, Dudoit Y, Le Mignot L, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010;160(2):240-5. DOI: 10.1111/j.1365-2249.2009.04079.x10.1111/j.1365-2249.2009.04079.x285794720041884Search in Google Scholar

52. Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: An evidence-based review. Drugs. 2013;73(12):1307-19. DOI: 10.1007/s40265-013-0094-310.1007/s40265-013-0094-323861187Search in Google Scholar

53. Torgerson TR, Bonagura VR, Shapiro RS. Clinical ambiguities - Ongoing questions. J Clin Immunol. 2013;33(2 SUPPL.):S99-S103. DOI: 10.1007/s10875-012-9851-410.1007/s10875-012-9851-423242829Search in Google Scholar

54. Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23(1):55-60. DOI: 10.1111/j.1365-3148.2012.01201.x10.1111/j.1365-3148.2012.01201.x358087923167310Search in Google Scholar

55. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol. 2010 Mar;30(2):301-7. DOI: 10.1007/s10875-009-9352-210.1007/s10875-009-9352-220082124Search in Google Scholar

56. Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, et al. Recombinant human hyaluronidase-fa cilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951-7. DOI: 10.1016/j. jaci.2012.06.021Search in Google Scholar

57. Chapel H, Gardulf A. Subcutaneous immunoglobulin replacement therapy: The European experience. Curr Opin Allergy Clin Immunol. 2013;13(6):623-9. DOI: 10.1097/ACI.000000000000001310.1097/ACI.000000000000001324126615Search in Google Scholar

58. Espanol T, Prevot J, Drabwell J, Sondhi S, Olding L. Improving current immunoglobulin therapy for patients with primary immunodeficiency: Quality of life and views on treatment. Patient Preference Adherence. 2014;8:621-9. DOI: 10.2147/PPA.S6077110.2147/PPA.S60771401437724833896Search in Google Scholar

59. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010 Oct;137(1):21-30. DOI: 10.1016/j.clim.2010.06.01210.1016/j.clim.2010.06.01220675197Search in Google Scholar

60. Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012 Aug;169(2):172-81. DOI: 10.1111/j.1365-2249.2012.04594.x10.1111/j.1365-2249.2012.04594.x340637722774992Search in Google Scholar

61. Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46(10):1547-54. DOI: 10.1086/58766910.1086/58766918419489Search in Google Scholar

62. Llobet MP, Soler-Palacin P, Detkova D, Hernandez M, Caragol I, Espanol T. Common variable immunodeficiency: 20-yr experience at a single centre. Pediatr Allergy Immunol. 2009 Mar;20(2):113-8. DOI: 10.1111/j.1399-3038.2008.00744.x10.1111/j.1399-3038.2008.00744.x18798799Search in Google Scholar

63. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: Results from a multicenter prospective cohort study. J Clin Immunol. 2011;31(3):315-22. DOI: 10.1007/s10875-011-9511-010.1007/s10875-011-9511-021365217Search in Google Scholar

64. Gregersen S, Aaløkken TM, Mynarek G, Fevang B, Holm AM, Ueland T, et al. Development of pulmonary abnormalities in patients with common variable immunodeficiency: associations with clinical and immunologic factors. Annals of Allergy, Asthma and Immunology. 2010;104(6):503-10. DOI: 10.1016/j. anai.2010.04.015Search in Google Scholar

65. Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, Fieschi C, et al. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: Correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol. 2013;171(2):186-94. DOI: 10.1111/ cei.1200210.1111/cei.12002357328923286945Search in Google Scholar

66. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008 Jul;122(1):210-2. DOI: 10.1016/j.jaci.2008.04.04410.1016/j.jaci.2008.04.04418602574Search in Google Scholar

67. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139(2):133-41. DOI: 10.1016/j.clim.2011.01.00610.1016/j.clim.2011.01.00621353644Search in Google Scholar

68. Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32(6):1153-64. DOI: 10.1007/s10875-012-9740-x10.1007/s10875-012-9740-x22828788Search in Google Scholar

69. Mouillot G, Carmagnat M, Gérard L, Garnier JL, Fieschi C, Vince N, et al. B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease. J Clin Immunol. 2010;30(5):746-55. DOI: 10.1007/s10875-010-9424-310.1007/s10875-010-9424-320437084Search in Google Scholar

70. Resnick ES, Moshier EL, Godbold JH, Cunningham- Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650-7. DOI: 10.1182/ blood-2011-09-37794510.1182/blood-2011-09-377945328634322180439Search in Google Scholar

71. Rapley P, Davidson PM. Enough of the problem: a review of time for health care transition solutions for young adults with a chronic illness. J Clin Nurs. 2010 Feb;19(3-4):313-23. DOI: 10.1111/j.1365-2702.2009.03027.x10.1111/j.1365-2702.2009.03027.x20500270Search in Google Scholar

72. Agarwal S, Cunningham-Rundles C. Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement. J Allergy Clin Immunol. 2013;131(6):1699-701. DOI: 10.1016/j.jaci.2013.01.03610.1016/j.jaci.2013.01.036410231223518142Search in Google Scholar

73. O’Mahony B, Turner A. The Dublin Consensus Statement 2011 on vital issues relating to the collection and provision of blood components and plasma-derived medicinal products. Vox Sang. 2012 Feb;102(2):140-3. DOI: 10.1111/j.1423-0410.2011.01528.x10.1111/j.1423-0410.2011.01528.x21806632Search in Google Scholar

74. Späth PJ, Van Holten RW, Kempf C. Pathogen safety of immunoglobulin preparations. In: Wahn V, Orange J, editors. Clinical Use of Immunoglobulins. 2nd ed. Bremen - London - Boston: UNI-MED Verlag; 2013. p.26-50.Search in Google Scholar

75. Vassilev TL, Bineva IL, Dietrich G, Kaveri SV, Kazatchkine MD. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun. 1995 Jun;8(3):405-13. DOI: 10.1006/jaut.1995.003210.1006/jaut.1995.00327576001Search in Google Scholar

76. Späth PJ, Lutz HU. Naturally occurring antibodies/ autoantibodies in polyclonal immunoglobulin concentrates. Lutz HU, editor. Naturally Occurring Antibodies (NAbs). Advances in Experimental Medicine and Biology[ 750], 239-261. 16-4-2012. Austin, TX USA, Lan des Bioscience and Springer Science+Business Media. Advances in Experimental Medicine and Biology.10.1007/978-1-4614-3461-0_1822903679Search in Google Scholar

77. Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol. Pract. 2013;1(6):558-66. DOI: 10.1016/j.jaip.2013.09.01210.1016/j.jaip.2013.09.01224565701Search in Google Scholar

78. Gürcan HM, Keskin DB, Ahmed AR. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev. 2010;9(8):553-9. DOI: 10.1016/j.autrev.2010.03.00310.1016/j.autrev.2010.03.00320346419Search in Google Scholar

79. Etscheid M, Breitner-Ruddock S, Gross S, Hunfeld A, Seitz R, Dodt J. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang. 2012 Jan;102(1):40-6. DOI: 10.1111/j.1423-0410.2011.01502.x10.1111/j.1423-0410.2011.01502.x21545600Search in Google Scholar

80. Desborough MJ, Miller J, Thorpe SJ, Murphy MF, Misbah SA. Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature. Transfus Med. 2013 Oct 25;E-pub ahead of print. DOI: 10.1111/ tme.12083Search in Google Scholar

81. Schroeder HW, Jr., Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infect. 2012;40(6):601-11. DOI: 10.1007/s15010-012-0323-910.1007/s15010-012-0323-9350119122968971Search in Google Scholar

82. Dhainaut F, Guillaumat PO, Dib H, Perret G, Sauger A, De Coupade C, et al. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang. 2013;104(2):115-26. DOI: 10.1111/j.1423-0410.2012.01648.x10.1111/j.1423-0410.2012.01648.x358088023003576Search in Google Scholar

83. Medical Advisory Committee of the Immune Deficiency Foundation, Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014 Apr;133(4):961-6. DOI: 10.1016/j.jaci.2013.11.04310.1016/j.jaci.2013.11.043400934724582311Search in Google Scholar

84. Worth AJJ, Booth C, Veys P. Stem cell transplantation for primary immune deficiency. Curr Opin Hematol. 2013;20(6):501-8. DOI: 10.1097/MOH.0b013e-328365a13bSearch in Google Scholar

85. Cavazzana-Calvo M, Andre-Schmutz I, Fischer A. Haematopoietic stem cell transplantation for SCID patients: Where do we stand? Br J Haematol. 2013;160(2):146-52. DOI: 10.1111/bjh.1211910.1111/bjh.12119Search in Google Scholar

86. Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014 Feb 1;383(9915):436-48. DOI: 10.1016/S0140-6736(13)62069-310.1016/S0140-6736(13)62069-3Search in Google Scholar

87. Lane JP, Evans PTG, Nademi Z, Barge D, Jackson A, Hambleton S, et al. Low-dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies. Biol Blood Marrow Transplant. 2014;20(2):243-9. DOI: 10.1016/j. bbmt.2013.11.005Search in Google Scholar

88. Zou J, Sweeney CL, Chou BK, Choi U, Pan J, Wang H, et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood. 2011 May 26;117(21):5561-72. DOI: 10.1182/blood-2010-12-32816110.1182/blood-2010-12-328161311002121411759Search in Google Scholar

89. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, Aiuti A. Gene therapy for primary immunodeficiencies: Part 1. Curr Opin Immunol 2012 Oct;24(5):580-4. DOI: 10.1016/j.coi.2012.08.00810.1016/j.coi.2012.08.00822981681Search in Google Scholar

90. Aiuti A, Bacchetta R, Seger R, Villa A, Cavazzana-Calvo M. Gene therapy for primary immunodeficiencies: Part 2. Curr Opin Immunol 2012 Oct;24(5):585-91. DOI: 10.1016/j.coi.2012.07.01210.1016/j.coi.2012.07.01222909900Search in Google Scholar

91. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy of primary T cell immunodeficiencies. Gene. 2013;525(2):170-3. DOI: 10.1016/j. gene.2013.03.092Search in Google Scholar

92. Touzot F, Hacein-Bey-Abina S, Fischer A, Cavazzana M. Gene therapy for inherited immunodeficiency. Expert Opin Biol Ther. 2014 Jun;14(6):789-98. DOI: 10.1517/14712598.2014.89581110.1517/14712598.2014.89581124823313Search in Google Scholar

93. Farinelli G, Capo V, Scaramuzza S, Aiuti A. Lentiviral vectors for the treatment of primary immunodeficiencies. J Inherit Metab Dis. 2014 Mar 12;Epub ahead of print. DOI: 10.1007/s10545-014-9690-y10.1007/s10545-014-9690-y24619149Search in Google Scholar

94. Mukherjee S, Thrasher AJ. Gene therapy for PIDs: progress, pitfalls and prospects. Gene. 2013 Aug 10;525(2):174-81. DOI: 10.1016/j.gene.2013.03.098 10.1016/j.gene.2013.03.098372541723566838Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo